Annette Nordenbo

Summary

Affiliation: Aarhus University Hospital
Country: Denmark

Publications

  1. ncbi request reprint A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    N Koch-Henriksen
    Danish Multiple Sclerosis Registry, Rigshospitalet, Copenhagen, Denmark
    Neurology 66:1056-60. 2006
  2. doi request reprint The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis
    N Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Denmark and The Danish MS Treatment Register, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 15:601-5. 2009
  3. doi request reprint The changing demographic pattern of multiple sclerosis epidemiology
    Nils Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Aalborg, Denmark
    Lancet Neurol 9:520-32. 2010
  4. ncbi request reprint CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis
    F Sellebjerg
    The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark
    Mult Scler 11:641-5. 2005
  5. ncbi request reprint Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
    P Soelberg Sorensen
    Copenhagen MS Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    Neurology 65:33-9. 2005
  6. ncbi request reprint Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis
    C Ross
    Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen, Denmark
    Mult Scler 12:39-46. 2006
  7. ncbi request reprint Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 13:616-21. 2007
  8. doi request reprint Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 14:837-42. 2008

Collaborators

  • Per Soelberg Sørensen
  • Egon Stenager
  • Mads Ravnborg
  • F Sellebjerg
  • N Koch-Henriksen
  • P S Sorensen
  • K Bendtzen
  • C Ross
  • Nils Koch-Henriksen
  • E M Flachs
  • K M Clemmesen
  • P Soelberg Sorensen
  • T Petersen
  • T Christensen
  • Finn Boesen
  • K Jensen
  • Jesper Tørring
  • Kai Jensen
  • J Frederiksen
  • Sven Deth
  • Ole Kristensen
  • T Hansen
  • Hans Jacob Hansen
  • Mogens Worm
  • A Heltberg
  • Jette Frederiksen
  • Bjarne Sivertsen
  • Nils Koch Henriksen
  • O Kristensen
  • Anne Heltberg

Detail Information

Publications8

  1. ncbi request reprint A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    N Koch-Henriksen
    Danish Multiple Sclerosis Registry, Rigshospitalet, Copenhagen, Denmark
    Neurology 66:1056-60. 2006
    ..To investigate whether the efficacy of interferon-beta (IFNbeta) treatment of relapsing-remitting MS (RR-MS) was influenced by type, dose, and frequency of administration...
  2. doi request reprint The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis
    N Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Denmark and The Danish MS Treatment Register, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 15:601-5. 2009
    ..To establish whether the clinical effect of neutralizing antibodies (NAbs) against interferon-beta (IFN beta) depends on the type of IFNbeta (1a or 1b) used for treatment of patients with relapsing-remitting multiple sclerosis (MS)...
  3. doi request reprint The changing demographic pattern of multiple sclerosis epidemiology
    Nils Koch-Henriksen
    Department of Neurology, Aarhus University Hospital in Aalborg, Aalborg, Denmark
    Lancet Neurol 9:520-32. 2010
    ..New insights into gene-environment and gene-gene interactions complicate interpretations of demographic epidemiology and have made obsolete the idea of simple causative associations between genes or the environment and MS...
  4. ncbi request reprint CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis
    F Sellebjerg
    The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark
    Mult Scler 11:641-5. 2005
    ..CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta...
  5. ncbi request reprint Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
    P Soelberg Sorensen
    Copenhagen MS Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
    Neurology 65:33-9. 2005
    ....
  6. ncbi request reprint Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis
    C Ross
    Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen, Denmark
    Mult Scler 12:39-46. 2006
    ..Neutralizing capacity CEA is less laborious and more economical than titre-based NAb assays and suitable for large-scale screenings of MS patients...
  7. ncbi request reprint Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 13:616-21. 2007
    ..With affinity maturation, NAbs effectively prevent IFN-beta binding to its receptors also in vivo and, hence, abolish the treatment effect...
  8. doi request reprint Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    P S Sorensen
    Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Mult Scler 14:837-42. 2008
    ....